SLNO vs. INMD, BLFS, LRMR, ZYXI, EDAP, RYTM, FONR, CNMD, RMTI, and BSGM
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include InMode (INMD), BioLife Solutions (BLFS), Larimar Therapeutics (LRMR), Zynex (ZYXI), Edap Tms (EDAP), Rhythm Pharmaceuticals (RYTM), FONAR (FONR), CONMED (CNMD), Rockwell Medical (RMTI), and BioSig Technologies (BSGM). These companies are all part of the "medical" sector.
Soleno Therapeutics (NASDAQ:SLNO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
Soleno Therapeutics received 140 more outperform votes than InMode when rated by MarketBeat users. However, 75.48% of users gave InMode an outperform vote while only 71.22% of users gave Soleno Therapeutics an outperform vote.
97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 23.7% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
InMode has a net margin of 40.22% compared to Soleno Therapeutics' net margin of 0.00%. InMode's return on equity of 29.80% beat Soleno Therapeutics' return on equity.
Soleno Therapeutics has a beta of -1.56, suggesting that its stock price is 256% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500.
InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
In the previous week, InMode had 10 more articles in the media than Soleno Therapeutics. MarketBeat recorded 13 mentions for InMode and 3 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 1.17 beat InMode's score of 0.13 indicating that Soleno Therapeutics is being referred to more favorably in the media.
Soleno Therapeutics presently has a consensus price target of $55.60, indicating a potential upside of 48.27%. InMode has a consensus price target of $32.80, indicating a potential upside of 88.40%. Given InMode's higher possible upside, analysts plainly believe InMode is more favorable than Soleno Therapeutics.
Summary
InMode beats Soleno Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
